Sugi Predict

Sugi Predict / Compounds / SCHEMBL6022600

SCHEMBL6022600

SCHEMBL6022600

COC(=O)C(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 12/20 0.72
▸ NR4A2 P43354 1/20 0.72
▸ MT-CO2 P00403 3/20 0.72
▸ PTGS1 P23219 4/20 0.61
▸ CA12 O43570 1/20 0.61
▸ CA1 P00915 1/20 0.61
▸ CA2 P00918 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ CA3 P07451 1/20 0.61
▸ ADRB2 P07550 1/20 0.61
▸ ADRB1 P08588 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ ADORA3 P0DMS8 1/20 0.61
▸ CHRM1 P11229 1/20 0.61
▸ ADRA2B P18089 1/20 0.61
▸ CA4 P22748 1/20 0.61
▸ CA6 P23280 1/20 0.61
▸ SLC6A2 P23975 1/20 0.61
▸ PDE4A P27815 1/20 0.61
▸ ADORA1 P30542 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5071849 0.90 PTGS2 (0.74) PTGS2NR4A2MT-CO2PTGS1CA12
SCHEMBL5071029 0.90 PTGS2 (0.77) PTGS2NR4A2MT-CO2PTGS1CA12
SCHEMBL5073588 0.89 PTGS2 (0.81) PTGS2NR4A2MT-CO2PTGS1CA12
SCHEMBL5069873 0.87 PTGS2 (0.77) PTGS2NR4A2MT-CO2PTGS1CA12
SCHEMBL5071833 0.87 PTGS2 (0.80) PTGS2NR4A2MT-CO2PTGS1CA12
SCHEMBL5069871 0.86 PTGS2 (0.78) PTGS2NR4A2MT-CO2PTGS1CA12
SCHEMBL13772645 0.85 PTGS2 (0.85) PTGS2NR4A2MT-CO2PTGS1CA12
SCHEMBL5071829 0.85 PTGS2 (0.78) PTGS2NR4A2MT-CO2PTGS1CA12
SCHEMBL5481289 0.84 PTGS2 (1.00) PTGS2NR4A2MT-CO2PTGS1CA12
Parecoxib SCHEMBL9529 0.84 PTGS2 (1.00) PTGS2NR4A2MT-CO2PTGS1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436967-B1 PREFERENTIAL CYCLOOXYGENASE INHIBITORS USED AS INJECTABLE ANALGESIC AND ANTIINFLAMMATORY AGENTS HAVING REDUCED SIDE EFFECTS; ACYLATION PHARMACIA CORPORATION 2002-08-20 — — US claimed
WO-1997038986-A1 SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS G.D. SEARLE & CO. (US) 1997-10-23 — — WO claimed
EP-3509604-B1 COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS TUFTS COLLEGE (US) 2026-02-18 — — EP disclosed
US-12478609-B2 Combination therapies using immuno-DASH inhibitors and PGE2 antagonists TRUSTEES OF TUFTS COLLEGE (US) 2025-11-25 — — US disclosed
US-20240277659-A1 COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS TRUSTEES OF TUFTS COLLEGE 2024-08-22 — — US disclosed
US-11957657-B2 Combination therapies using immuno-dash inhibitors and PGE2 antagonists TRUSTEES OF TUFTS COLLEGE (US) 2024-04-16 — — US disclosed
US-20230390241-A1 DASH INHIBITORS, AND USES RELATED THERETO TRUSTEES OF TUFTS COLLEGE 2023-12-07 — — US disclosed
US-20230372372-A1 COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS TRUSTEES OF TUFTS COLLEGE 2023-11-23 — — US disclosed
US-11583516-B2 Dash inhibitors, and uses related thereto TRUSTEES OF TUFTS COLLEGE (US) 2023-02-21 — — US disclosed
US-11559537-B2 Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists TRUSTEES OF TUFTS COLLEGE (US) 2023-01-24 — — US disclosed
US-20220040149-A1 COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS TRUSTEES OF TUFTS COLLEGE 2022-02-10 — — US disclosed
WO-2004093870-A1 TREATMENT AND PREVENTION OF OTIC DISORDERS PHARMACIA CORPORATION (US) 2004-11-04 — — WO disclosed
US-20040220155-A1 Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith PHARMACIA CORPORATION 2004-11-04 — — US disclosed
WO-2004094373-A2 A METHOD OF PROVIDING A STEROID-SPARING BENEFIT WITH A CYCLOOXYGENASE-2 INHIBITOR AND COMPOSITIONS THEREWITH PHARMACIA CORPORATION (US) 2004-11-04 — — WO disclosed
US-20040204472-A1 Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents PHARMACIA CORPORATION 2004-10-14 — — US disclosed
US-20040204471-A1 Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents PHARMACIA CORPORATION (US) 2004-10-14 — — US disclosed
WO-2004078113-A2 TREATMENT AND PREVENTION OF OBESITY WITH COX-2 INHIBITORS ALONE OR IN COMBINATION WITH WEIGHT-LOSS AGENTS PHARMACIA CORPORATION (US) 2004-09-16 — — WO disclosed
US-20040147581-A1 Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy PHARMACIA CORPORATION (US) 2004-07-29 — — US disclosed
WO-2004045509-A2 METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY PHARMACIA CORPORATION (US) 2004-06-03 — — WO disclosed
WO-1997038986-A1 SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS G.D. SEARLE & CO. (US) 1997-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277659-A1 COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS HPGDS, PTGIS, PTGDR2 PTGS2 19/4885NR4A2 1592/4885MT-CO2 4791/4885
US-12478609-B2 Combination therapies using immuno-DASH inhibitors and PGE2 antagonists HPGDS, PTGIS, PTGDR2 PTGS2 19/4885NR4A2 1592/4885MT-CO2 4791/4885
US-20230390241-A1 DASH INHIBITORS, AND USES RELATED THERETO CD2BP2, PCNA, CD2 PTGS2 2358/4885NR4A2 3600/4885MT-CO2 4828/4885
US-11583516-B2 Dash inhibitors, and uses related thereto PCNA, CD2BP2, CCNO PTGS2 2466/4885NR4A2 3671/4885MT-CO2 4806/4885
US-20040147581-A1 Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy HTR2A, HTR1A, TPH2 PTGS2 19/4885NR4A2 590/4885MT-CO2 845/4885
US-20040204472-A1 Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents PTGS2, PTGES2, PTGS1 PTGS2 1/4885NR4A2 2294/4885MT-CO2 105/4885
US-11559537-B2 Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists CASP1, CASP2, APAF1 PTGS2 24/4885NR4A2 2592/4885MT-CO2 2825/4885
US-20230372372-A1 COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS CASP1, CASP2, APAF1 PTGS2 24/4885NR4A2 2592/4885MT-CO2 2825/4885
US-20220040149-A1 COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS HPGDS, PTGIS, PTGDR2 PTGS2 19/4885NR4A2 1592/4885MT-CO2 4791/4885
US-11957657-B2 Combination therapies using immuno-dash inhibitors and PGE2 antagonists HPGDS, PTGIS, PTGDR2 PTGS2 19/4885NR4A2 1592/4885MT-CO2 4791/4885
US-20040204471-A1 Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents OTC, PTGS2, PTGES2 PTGS2 2/4885NR4A2 2131/4885MT-CO2 19/4885
US-20040220155-A1 Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith CYP21A2, CYP17A1, CYP11B2 PTGS2 10/4885NR4A2 2259/4885MT-CO2 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.